| Business Summary | | BioSpecifics
Technologies
Corp.
is
engaged
in
the
business
of
producing
and
licensing
for
sale
by
others
a
fermentation
derived
enzyme
named
Collagenase
ABC,
which
is
approved
by
the
U.S.
Food
and
Drug
Administration,
and
researching
and
developing
additional
products
derived
from
this
enzyme
for
potential
use
as
pharmaceuticals.
The
Company
currently
derives
substantially
all
of
its
revenues
through
a
license
agreement
with
a
pharmaceutical
company
in
the
United
States,
Knoll
Pharmaceutical
Company.
These
revenues
are
derived
from
two
sources:
sales
of
Collagenase
ABC
enzyme
in
powder
form;
and
royalties
derived
from
sales
of
Collagenase
Santyl
Ointment,
which
contains
the
product. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BioSpecifics
Technologies
Corp.
is
engaged
in
the
business
of
producing
and
licensing
for
sale
by
others
a
fermentation
derived
enzyme
named
Collagenase
ABC,
as
well
as
the
researching
and
developing
of
additional
products
derived
from
this
enzyme.
For
the
three
months
ended
4/30/01,
revenues
rose
94%
to
$2.8
million.
Net
income
totaled
$175
thousand,
vs.
a
loss
of
$66
thousand.
Results
reflect
the
sales
of
Collagenase
ABC
to
KPC,
and
higher
margins. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Edwin Wegman, 81 Chairman
and Pres | $413K | Thomas Wegman, 46 Director
and Exec. VP | 210K | Albert Horcher, 41 Sec.,
Treasurer, CFO, Chief Accounting Officer | 123K | Dollar
amounts are as of 31-Jan-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|